WO2022173329A1 - Производные 2-ацетамидо-6-гидрокси-бензотиофена, обладающие противовирусной активностью - Google Patents
Производные 2-ацетамидо-6-гидрокси-бензотиофена, обладающие противовирусной активностью Download PDFInfo
- Publication number
- WO2022173329A1 WO2022173329A1 PCT/RU2022/050030 RU2022050030W WO2022173329A1 WO 2022173329 A1 WO2022173329 A1 WO 2022173329A1 RU 2022050030 W RU2022050030 W RU 2022050030W WO 2022173329 A1 WO2022173329 A1 WO 2022173329A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxy
- benzothiophene
- mass
- yield
- nch
- Prior art date
Links
- PVVURZCENXWGAR-UHFFFAOYSA-N N-(6-hydroxy-1-benzothiophen-2-yl)acetamide Chemical class C(C)(=O)NC=1SC2=C(C=1)C=CC(=C2)O PVVURZCENXWGAR-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 22
- 241000700605 Viruses Species 0.000 claims abstract description 43
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 10
- 241000711573 Coronaviridae Species 0.000 claims abstract description 10
- 230000000241 respiratory effect Effects 0.000 claims abstract description 6
- 208000037797 influenza A Diseases 0.000 claims abstract description 4
- 208000025721 COVID-19 Diseases 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 37
- 238000002360 preparation method Methods 0.000 claims description 28
- 206010022000 influenza Diseases 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 13
- 208000036142 Viral infection Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 7
- 241000712431 Influenza A virus Species 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 56
- 230000003612 virological effect Effects 0.000 abstract description 8
- 241001493065 dsRNA viruses Species 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 77
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- 239000003921 oil Substances 0.000 description 38
- 239000000243 solution Substances 0.000 description 38
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 36
- 229940079593 drug Drugs 0.000 description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 23
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 22
- 239000002244 precipitate Substances 0.000 description 21
- 235000019441 ethanol Nutrition 0.000 description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- -1 compounds derivatives of 2-acetamido-6-hydroxy-benzothiophene Chemical class 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 239000003443 antiviral agent Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000000725 suspension Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 229960003752 oseltamivir Drugs 0.000 description 9
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 6
- 239000002911 sialidase inhibitor Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229910052796 boron Inorganic materials 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 201000010740 swine influenza Diseases 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 4
- 229960004626 umifenovir Drugs 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- FIDLLEYNNRGVFR-CTNGQTDRSA-N (3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-11-hydroxy-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-9,12-dione Chemical compound OC1=C2N(C=CC1=O)N([C@@H]1COCCN1C2=O)[C@@H]1C2=C(SCC3=C1C=CC(F)=C3F)C=CC=C2 FIDLLEYNNRGVFR-CTNGQTDRSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229960003805 amantadine Drugs 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 229940121357 antivirals Drugs 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 208000037801 influenza A (H1N1) Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 206010058667 Oral toxicity Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- RZVPBGBYGMDSBG-GGAORHGYSA-N baloxavir marboxil Chemical compound COC(=O)OCOc1c2C(=O)N3CCOC[C@H]3N([C@H]3c4ccc(F)c(F)c4CSc4ccccc34)n2ccc1=O RZVPBGBYGMDSBG-GGAORHGYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- VETPBFPRKAXOFI-UHFFFAOYSA-N methyl 2-[acetyl(benzyl)amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CC1=CC=CC=C1)C1=C(C(OC)=O)C(C=CC(O)=C2)=C2S1)=O VETPBFPRKAXOFI-UHFFFAOYSA-N 0.000 description 2
- WLYWYNRNUKJTQW-UHFFFAOYSA-N methyl 2-[acetyl(benzyl)amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical class CC(N(CC1=CC=CC=C1)C1=C(C(OC)=O)C(C=CC(O)=C2Cl)=C2S1)=O WLYWYNRNUKJTQW-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 description 2
- 229960001084 peramivir Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- FQMLTEAEJZVTAJ-UHFFFAOYSA-M sodium;2-(9-oxoacridin-10-yl)acetate Chemical compound [Na+].C1=CC=C2N(CC(=O)[O-])C3=CC=CC=C3C(=O)C2=C1 FQMLTEAEJZVTAJ-UHFFFAOYSA-M 0.000 description 2
- HPRAYQNGLXYUQM-UHFFFAOYSA-N spiro[4.5]decane-1,4,8-trione Chemical compound O=C1CCC(=O)C11CCC(=O)CC1 HPRAYQNGLXYUQM-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940061367 tamiflu Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 2
- CWGBFIRHYJNILV-UHFFFAOYSA-N (1,4-diphenyl-1,2,4-triazol-4-ium-3-yl)-phenylazanide Chemical compound C=1C=CC=CC=1[N-]C1=NN(C=2C=CC=CC=2)C=[N+]1C1=CC=CC=C1 CWGBFIRHYJNILV-UHFFFAOYSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- WVCGYDKXFIDZQF-UHFFFAOYSA-N 1-amino-2-(1,7,7-trimethyl-2-bicyclo[2.2.1]heptanylidene)ethanol Chemical compound CC12C(CC(CC1)C2(C)C)=CC(O)N WVCGYDKXFIDZQF-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- DRZLMACKRQCZPW-UHFFFAOYSA-N 2'-acetamidospiro[1,3-dioxolane-2,6'-5,7-dihydro-4H-1-benzothiophene]-3'-carboxylic acid Chemical class C1CC=2C(C(O)=O)=C(NC(=O)C)SC=2CC21OCCO2 DRZLMACKRQCZPW-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- IEPSIZXKROLHPR-UHFFFAOYSA-N 2-[acetyl(benzyl)amino]-6-hydroxy-1-benzothiophene-3-carboxamide Chemical compound CC(N(CC1=CC=CC=C1)C1=C(C(N)=O)C(C=CC(O)=C2)=C2S1)=O IEPSIZXKROLHPR-UHFFFAOYSA-N 0.000 description 1
- NQBWQRXZSGBQJC-UHFFFAOYSA-N 2-[acetyl(benzyl)amino]-6-hydroxy-N-methyl-1-benzothiophene-3-carboxamide Chemical compound CC(N(CC1=CC=CC=C1)C1=C(C(NC)=O)C(C=CC(O)=C2)=C2S1)=O NQBWQRXZSGBQJC-UHFFFAOYSA-N 0.000 description 1
- VYNNIHUCVHEZIW-UHFFFAOYSA-N 2-[acetyl(benzyl)amino]-7-[(dimethylamino)methyl]-6-hydroxy-N-methyl-1-benzothiophene-3-carboxamide Chemical compound CC(N(CC1=CC=CC=C1)C1=C(C(NC)=O)C(C=CC(O)=C2CN(C)C)=C2S1)=O VYNNIHUCVHEZIW-UHFFFAOYSA-N 0.000 description 1
- GVPNJJKNLFPLBT-UHFFFAOYSA-N 2-[acetyl(benzyl)amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylic acid Chemical compound CC(N(CC1=CC=CC=C1)C1=C(C(O)=O)C(C=CC(O)=C2Cl)=C2S1)=O GVPNJJKNLFPLBT-UHFFFAOYSA-N 0.000 description 1
- UMIJDWMFAVYDOI-UHFFFAOYSA-N 2-[acetyl(benzyl)amino]-7-chloro-6-hydroxy-N-methyl-1-benzothiophene-3-carboxamide Chemical compound CC(N(CC1=CC=CC=C1)C1=C(C(NC)=O)C(C=CC(O)=C2Cl)=C2S1)=O UMIJDWMFAVYDOI-UHFFFAOYSA-N 0.000 description 1
- AAEZXLRUUWGFFT-UHFFFAOYSA-N 2-[acetyl(benzyl)amino]-N-ethyl-6-hydroxy-1-benzothiophene-3-carboxamide Chemical compound CCNC(C1=C(N(CC2=CC=CC=C2)C(C)=O)SC2=C1C=CC(O)=C2)=O AAEZXLRUUWGFFT-UHFFFAOYSA-N 0.000 description 1
- YIPWUKXXARRKTN-UHFFFAOYSA-N 2-[acetyl-[(2-chlorophenyl)methyl]amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylic acid Chemical compound CC(N(CC(C=CC=C1)=C1Cl)C1=C(C(O)=O)C(C=CC(O)=C2Cl)=C2S1)=O YIPWUKXXARRKTN-UHFFFAOYSA-N 0.000 description 1
- QLERTYWUVYSIOQ-UHFFFAOYSA-N 2-[acetyl-[(2-fluorophenyl)methyl]amino]-6-hydroxy-1-benzothiophene-3-carboxylic acid Chemical compound CC(N(CC(C=CC=C1)=C1F)C1=C(C(O)=O)C(C=CC(O)=C2)=C2S1)=O QLERTYWUVYSIOQ-UHFFFAOYSA-N 0.000 description 1
- OOAIYZRVPZXXLG-UHFFFAOYSA-N 2-[acetyl-[(2-fluorophenyl)methyl]amino]-6-hydroxy-N-methyl-1-benzothiophene-3-carboxamide Chemical compound CC(N(CC(C=CC=C1)=C1F)C1=C(C(NC)=O)C(C=CC(O)=C2)=C2S1)=O OOAIYZRVPZXXLG-UHFFFAOYSA-N 0.000 description 1
- SAYMJYVMIVKKEH-UHFFFAOYSA-N 2-[acetyl-[(2-fluorophenyl)methyl]amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylic acid Chemical compound CC(N(CC(C=CC=C1)=C1F)C1=C(C(O)=O)C(C=CC(O)=C2Cl)=C2S1)=O SAYMJYVMIVKKEH-UHFFFAOYSA-N 0.000 description 1
- PROCBSUJCGYZGZ-UHFFFAOYSA-N 2-[acetyl-[(4-fluorophenyl)methyl]amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylic acid Chemical compound CC(N(CC(C=C1)=CC=C1F)C1=C(C(O)=O)C(C=CC(O)=C2Cl)=C2S1)=O PROCBSUJCGYZGZ-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- IDVQGNMSSHPZSJ-UHFFFAOYSA-N 7-methylsulfanyl-3-nitro-6h-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-one Chemical compound N1=C([N+]([O-])=O)C(=O)N2NC(SC)=NC2=N1 IDVQGNMSSHPZSJ-UHFFFAOYSA-N 0.000 description 1
- 241000380131 Ammophila arenaria Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- AEFVFJAYDZMORF-UHFFFAOYSA-N CC(N(CC1=CC=CC=C1)C1=C(C(O)=O)C(C=CC(O)=C2)=C2S1)=O Chemical compound CC(N(CC1=CC=CC=C1)C1=C(C(O)=O)C(C=CC(O)=C2)=C2S1)=O AEFVFJAYDZMORF-UHFFFAOYSA-N 0.000 description 1
- NGTWKCNJTLJUGH-UHFFFAOYSA-N CC(N(CC1=CC=CC=C1)C1=C(C(O)=O)C(CCC2(C3)OCCO2)=C3S1)=O Chemical class CC(N(CC1=CC=CC=C1)C1=C(C(O)=O)C(CCC2(C3)OCCO2)=C3S1)=O NGTWKCNJTLJUGH-UHFFFAOYSA-N 0.000 description 1
- GMNJHWIVJTWWTC-UHFFFAOYSA-N CCCNC(C1=C(N(CC2=CC=CC=C2)C(C)=O)SC2=C1C=CC(O)=C2)=O Chemical compound CCCNC(C1=C(N(CC2=CC=CC=C2)C(C)=O)SC2=C1C=CC(O)=C2)=O GMNJHWIVJTWWTC-UHFFFAOYSA-N 0.000 description 1
- URELERHXNHMQJO-UHFFFAOYSA-N CCOC(=O)C1=C(SC2=C1C=CC(=C2)O)NC(=O)C Chemical compound CCOC(=O)C1=C(SC2=C1C=CC(=C2)O)NC(=O)C URELERHXNHMQJO-UHFFFAOYSA-N 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229940123734 Endonuclease inhibitor Drugs 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000197306 H1N1 subtype Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- NXRSMUUNXKECRU-UHFFFAOYSA-N N-benzyl-N-[7-chloro-6-hydroxy-3-(piperidine-1-carbonyl)-1-benzothiophen-2-yl]acetamide Chemical compound CC(N(CC1=CC=CC=C1)C1=C(C(N2CCCCC2)=O)C(C=CC(O)=C2Cl)=C2S1)=O NXRSMUUNXKECRU-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- OZBDFBJXRJWNAV-UHFFFAOYSA-N Rimantadine hydrochloride Chemical compound Cl.C1C(C2)CC3CC2CC1(C(N)C)C3 OZBDFBJXRJWNAV-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- 108700010756 Viral Polyproteins Proteins 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- NXLMTQNTFFHJQV-UHFFFAOYSA-N [2-[acetyl(benzyl)amino]-3-cyano-1-benzothiophen-6-yl] acetate Chemical compound CC(N(CC1=CC=CC=C1)C(SC1=C2C=CC(OC(C)=O)=C1)=C2C#N)=O NXLMTQNTFFHJQV-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 101150054399 ace2 gene Proteins 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000143 anti-replicative effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940008411 baloxavir marboxil Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- RIOXQFHNBCKOKP-UHFFFAOYSA-N benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- OAIVIYSBZFEOIU-UHFFFAOYSA-N chloroform;propan-2-one Chemical compound CC(C)=O.ClC(Cl)Cl OAIVIYSBZFEOIU-UHFFFAOYSA-N 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 229960000459 cridanimod Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 1
- MDLPUSVEFZJCSV-UHFFFAOYSA-N dimethyl 2-(propanoylamino)-5,6-dihydro-4h-cyclopenta[b]thiophene-3,4-dicarboxylate Chemical compound C1CC(C(=O)OC)C2=C1SC(NC(=O)CC)=C2C(=O)OC MDLPUSVEFZJCSV-UHFFFAOYSA-N 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940052761 dopaminergic adamantane derivative Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- STVYPZZQOXPZBX-UHFFFAOYSA-N ethanol;hexane;hydrate Chemical compound O.CCO.CCCCCC STVYPZZQOXPZBX-UHFFFAOYSA-N 0.000 description 1
- HATAXVHWNRVHSI-UHFFFAOYSA-N ethyl 2'-aminospiro[1,3-dioxolane-2,6'-5,7-dihydro-4h-1-benzothiophene]-3'-carboxylate Chemical compound C1CC=2C(C(=O)OCC)=C(N)SC=2CC21OCCO2 HATAXVHWNRVHSI-UHFFFAOYSA-N 0.000 description 1
- XQTDSTKCPGIUHQ-UHFFFAOYSA-N ethyl 2-[acetyl(benzyl)amino]-5-bromo-6-methoxy-1-benzothiophene-3-carboxylate Chemical compound CCOC(C1=C(N(CC2=CC=CC=C2)C(C)=O)SC(C=C2OC)=C1C=C2Br)=O XQTDSTKCPGIUHQ-UHFFFAOYSA-N 0.000 description 1
- BRRNKXFPJQTVFG-UHFFFAOYSA-N ethyl 2-[acetyl(benzyl)amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CCOC(C1=C(N(CC2=CC=CC=C2)C(C)=O)SC2=C1C=CC(O)=C2)=O BRRNKXFPJQTVFG-UHFFFAOYSA-N 0.000 description 1
- KXFDNLDZZQDTPU-UHFFFAOYSA-N ethyl 2-[acetyl(benzyl)amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CCOC(C1=C(N(CC2=CC=CC=C2)C(C)=O)SC2=C1C=CC(O)=C2Cl)=O KXFDNLDZZQDTPU-UHFFFAOYSA-N 0.000 description 1
- VKPOQBBSLAHHLV-UHFFFAOYSA-N ethyl 2-[acetyl-[(2-chlorophenyl)methyl]amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CCOC(C1=C(N(CC(C=CC=C2)=C2Cl)C(C)=O)SC2=C1C=CC(O)=C2)=O VKPOQBBSLAHHLV-UHFFFAOYSA-N 0.000 description 1
- VHWNVVDSAHMYAK-UHFFFAOYSA-N ethyl 2-[acetyl-[(2-chlorophenyl)methyl]amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CCOC(C1=C(N(CC(C=CC=C2)=C2Cl)C(C)=O)SC2=C1C=CC(O)=C2Cl)=O VHWNVVDSAHMYAK-UHFFFAOYSA-N 0.000 description 1
- SABXWBNBXDTDLN-UHFFFAOYSA-N ethyl 2-[acetyl-[(4-chlorophenyl)methyl]amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CCOC(C1=C(N(CC(C=C2)=CC=C2Cl)C(C)=O)SC2=C1C=CC(O)=C2)=O SABXWBNBXDTDLN-UHFFFAOYSA-N 0.000 description 1
- ZPOXGSBZXPEPMD-UHFFFAOYSA-N ethyl 2-[acetyl-[(4-chlorophenyl)methyl]amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CCOC(C1=C(N(CC(C=C2)=CC=C2Cl)C(C)=O)SC2=C1C=CC(O)=C2Cl)=O ZPOXGSBZXPEPMD-UHFFFAOYSA-N 0.000 description 1
- HWMXRFUUPKUMNM-UHFFFAOYSA-N ethyl 2-[acetyl-[(4-methylphenyl)methyl]amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CCOC(C1=C(N(CC2=CC=C(C)C=C2)C(C)=O)SC2=C1C=CC(O)=C2)=O HWMXRFUUPKUMNM-UHFFFAOYSA-N 0.000 description 1
- YKSYZZBDBPSTSR-UHFFFAOYSA-N ethyl 2-[acetyl-[(4-methylphenyl)methyl]amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CCOC(C1=C(N(CC2=CC=C(C)C=C2)C(C)=O)SC2=C1C=CC(O)=C2Cl)=O YKSYZZBDBPSTSR-UHFFFAOYSA-N 0.000 description 1
- WIZQRLPGRPPOJL-UHFFFAOYSA-N ethyl 2-acetamido-5-bromo-6-methoxy-1-benzothiophene-3-carboxylate Chemical compound CCOC(C1=C(NC(C)=O)SC(C=C2OC)=C1C=C2Br)=O WIZQRLPGRPPOJL-UHFFFAOYSA-N 0.000 description 1
- LKULFGFVXMJGKO-UHFFFAOYSA-N ethyl 2-amino-5-bromo-6-methoxy-1-benzothiophene-3-carboxylate Chemical compound CCOC(C1=C(N)SC(C=C2OC)=C1C=C2Br)=O LKULFGFVXMJGKO-UHFFFAOYSA-N 0.000 description 1
- FJHBBRDAUPCXFT-UHFFFAOYSA-N ethyl 2-amino-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CCOC(=O)c1c(N)sc2cc(O)ccc12 FJHBBRDAUPCXFT-UHFFFAOYSA-N 0.000 description 1
- IWVMBAUTNRSMEI-UHFFFAOYSA-N ethyl 2-amino-6-methoxy-1-benzothiophene-3-carboxylate Chemical compound COC1=CC=C2C(C(=O)OCC)=C(N)SC2=C1 IWVMBAUTNRSMEI-UHFFFAOYSA-N 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- FUCALGBIMOACQB-UHFFFAOYSA-N ethyl 6-methoxy-2-(methylamino)-1-benzothiophene-3-carboxylate Chemical compound CCOC(C1=C(NC)SC2=C1C=CC(OC)=C2)=O FUCALGBIMOACQB-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 231100000771 fixed dose procedure Toxicity 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000286 interferogenic effect Effects 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- NPURPEXKKDAKIH-UHFFFAOYSA-N iodoimino(oxo)methane Chemical compound IN=C=O NPURPEXKKDAKIH-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229950004244 laninamivir Drugs 0.000 description 1
- UKTIJASCFRNWCB-RMIBSVFLSA-N laninamivir octanoate hydrate Chemical compound CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O UKTIJASCFRNWCB-RMIBSVFLSA-N 0.000 description 1
- 229950005327 laninamivir octanoate hydrate Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- XGKGIZXZNMVNPH-UHFFFAOYSA-N methyl 2'-[acetyl-[[2-(trifluoromethyl)phenyl]methyl]amino]spiro[1,3-dioxolane-2,6'-5,7-dihydro-4H-1-benzothiophene]-3'-carboxylate Chemical compound CC(N(CC1=C(C(F)(F)F)C=CC=C1)C1=C(C(OC)=O)C(CCC2(C3)OCCO2)=C3S1)=O XGKGIZXZNMVNPH-UHFFFAOYSA-N 0.000 description 1
- PXHNEEQKSDAREM-UHFFFAOYSA-N methyl 2'-acetamidospiro[1,3-dioxolane-2,6'-5,7-dihydro-4H-1-benzothiophene]-3'-carboxylate Chemical compound CC(NC1=C(C(OC)=O)C(CCC2(C3)OCCO2)=C3S1)=O PXHNEEQKSDAREM-UHFFFAOYSA-N 0.000 description 1
- VMSYIFPLNFZMMV-UHFFFAOYSA-N methyl 2'-aminospiro[1,3-dioxolane-2,6'-5,7-dihydro-4H-1-benzothiophene]-3'-carboxylate Chemical compound COC(=O)C=1C2=C(SC=1N)CC1(OCCO1)CC2 VMSYIFPLNFZMMV-UHFFFAOYSA-N 0.000 description 1
- ROQXOBFTNINKNP-UHFFFAOYSA-N methyl 2-[acetyl(1-phenylethyl)amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(C1=CC=CC=C1)N(C(C)=O)C1=C(C(OC)=O)C(C=CC(O)=C2)=C2S1 ROQXOBFTNINKNP-UHFFFAOYSA-N 0.000 description 1
- YEDMNNBTCJZSTD-UHFFFAOYSA-N methyl 2-[acetyl(1-phenylethyl)amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(C1=CC=CC=C1)N(C(C)=O)C1=C(C(OC)=O)C(C=CC(O)=C2Cl)=C2S1 YEDMNNBTCJZSTD-UHFFFAOYSA-N 0.000 description 1
- OIBAKDFLGQGLFZ-UHFFFAOYSA-N methyl 2-[acetyl(2-phenylethyl)amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CCC1=CC=CC=C1)C1=C(C(OC)=O)C(C=CC(O)=C2)=C2S1)=O OIBAKDFLGQGLFZ-UHFFFAOYSA-N 0.000 description 1
- REUMTQJAQFNANY-UHFFFAOYSA-N methyl 2-[acetyl(2-phenylethyl)amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CCC1=CC=CC=C1)C1=C(C(OC)=O)C(C=CC(O)=C2Cl)=C2S1)=O REUMTQJAQFNANY-UHFFFAOYSA-N 0.000 description 1
- DLHGUHXOEBUXHV-UHFFFAOYSA-N methyl 2-[acetyl(naphthalen-2-ylmethyl)amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CC1=CC2=CC=CC=C2C=C1)C1=C(C(OC)=O)C(C=CC(O)=C2Cl)=C2S1)=O DLHGUHXOEBUXHV-UHFFFAOYSA-N 0.000 description 1
- YEYVDLIUQSZUKV-UHFFFAOYSA-N methyl 2-[acetyl-[(2,4-difluorophenyl)methyl]amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CC(C=CC(F)=C1)=C1F)C1=C(C(OC)=O)C(C=CC(O)=C2Cl)=C2S1)=O YEYVDLIUQSZUKV-UHFFFAOYSA-N 0.000 description 1
- YFNIBAMEHFZREV-UHFFFAOYSA-N methyl 2-[acetyl-[(2-chlorophenyl)methyl]amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CC(C=CC=C1)=C1Cl)C1=C(C(OC)=O)C(C=CC(O)=C2)=C2S1)=O YFNIBAMEHFZREV-UHFFFAOYSA-N 0.000 description 1
- LXMZFUGXJIWWGO-UHFFFAOYSA-N methyl 2-[acetyl-[(2-chlorophenyl)methyl]amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CC(C=CC=C1)=C1Cl)C1=C(C(OC)=O)C(C=CC(O)=C2Cl)=C2S1)=O LXMZFUGXJIWWGO-UHFFFAOYSA-N 0.000 description 1
- MIGJAKVJNRCJJW-UHFFFAOYSA-N methyl 2-[acetyl-[(2-cyanophenyl)methyl]amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CC(C=CC=C1)=C1C#N)C1=C(C(OC)=O)C(C=CC(O)=C2)=C2S1)=O MIGJAKVJNRCJJW-UHFFFAOYSA-N 0.000 description 1
- ORMXHEJPDUCKTE-UHFFFAOYSA-N methyl 2-[acetyl-[(2-fluorophenyl)methyl]amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CC(C=CC=C1)=C1F)C1=C(C(OC)=O)C(C=CC(O)=C2)=C2S1)=O ORMXHEJPDUCKTE-UHFFFAOYSA-N 0.000 description 1
- FLZPROHXTZJCNP-UHFFFAOYSA-N methyl 2-[acetyl-[(2-methylphenyl)methyl]amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CC1=C(C)C=CC=C1)C1=C(C(OC)=O)C(C=CC(O)=C2)=C2S1)=O FLZPROHXTZJCNP-UHFFFAOYSA-N 0.000 description 1
- YVYSFGNUZYSDKK-UHFFFAOYSA-N methyl 2-[acetyl-[(3-fluorophenyl)methyl]amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CC1=CC(F)=CC=C1)C1=C(C(OC)=O)C(C=CC(O)=C2)=C2S1)=O YVYSFGNUZYSDKK-UHFFFAOYSA-N 0.000 description 1
- FDGMAXGWBILVAH-UHFFFAOYSA-N methyl 2-[acetyl-[(4-fluorophenyl)methyl]amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CC(C=C1)=CC=C1F)C1=C(C(OC)=O)C(C=CC(O)=C2)=C2S1)=O FDGMAXGWBILVAH-UHFFFAOYSA-N 0.000 description 1
- RGHFHCXLVAKVFB-UHFFFAOYSA-N methyl 2-[acetyl-[(4-methylphenyl)methyl]amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CC1=CC=C(C)C=C1)C1=C(C(OC)=O)C(C=CC(O)=C2)=C2S1)=O RGHFHCXLVAKVFB-UHFFFAOYSA-N 0.000 description 1
- XGIAHKPGBFMYKC-UHFFFAOYSA-N methyl 2-[acetyl-[(4-methylphenyl)methyl]amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CC1=CC=C(C)C=C1)C1=C(C(OC)=O)C(C=CC(O)=C2Cl)=C2S1)=O XGIAHKPGBFMYKC-UHFFFAOYSA-N 0.000 description 1
- HQDXLXNTXCGGRB-UHFFFAOYSA-N methyl 2-[acetyl-[(4-propan-2-ylphenyl)methyl]amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(C)C1=CC=C(CN(C(C)=O)C2=C(C(OC)=O)C(C=CC(O)=C3)=C3S2)C=C1 HQDXLXNTXCGGRB-UHFFFAOYSA-N 0.000 description 1
- LCKCKSUARZNYQJ-UHFFFAOYSA-N methyl 2-[acetyl-[2-(2-fluorophenyl)ethyl]amino]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CCC(C=CC=C1)=C1F)C1=C(C(OC)=O)C(C=CC(O)=C2)=C2S1)=O LCKCKSUARZNYQJ-UHFFFAOYSA-N 0.000 description 1
- SMTRHOPSDXTUDW-UHFFFAOYSA-N methyl 2-[acetyl-[2-(2-fluorophenyl)ethyl]amino]-7-[(dimethylamino)methyl]-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CCC(C=CC=C1)=C1F)C1=C(C(OC)=O)C(C=CC(O)=C2CN(C)C)=C2S1)=O SMTRHOPSDXTUDW-UHFFFAOYSA-N 0.000 description 1
- BVVYQRAXJLANOX-UHFFFAOYSA-N methyl 2-[acetyl-[[2-(trifluoromethyl)phenyl]methyl]amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CC1=C(C(F)(F)F)C=CC=C1)C1=C(C(OC)=O)C(C=CC(O)=C2Cl)=C2S1)=O BVVYQRAXJLANOX-UHFFFAOYSA-N 0.000 description 1
- CRUOSDLODMQDTH-UHFFFAOYSA-N methyl 2-[acetyl-[[4-(trifluoromethyl)phenyl]methyl]amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(N(CC1=CC=C(C(F)(F)F)C=C1)C1=C(C(OC)=O)C(C=CC(O)=C2Cl)=C2S1)=O CRUOSDLODMQDTH-UHFFFAOYSA-N 0.000 description 1
- YQJLDAKZPWHHFN-UHFFFAOYSA-N methyl 4,5-dimethyl-2-[[5-[2-(trifluoromethyl)phenyl]furan-2-carbonyl]amino]thiophene-3-carboxylate Chemical compound CC1=C(C)SC(NC(=O)C=2OC(=CC=2)C=2C(=CC=CC=2)C(F)(F)F)=C1C(=O)OC YQJLDAKZPWHHFN-UHFFFAOYSA-N 0.000 description 1
- ANGDWNBGPBMQHW-UHFFFAOYSA-N methyl cyanoacetate Chemical compound COC(=O)CC#N ANGDWNBGPBMQHW-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 125000006504 o-cyanobenzyl group Chemical group [H]C1=C([H])C(C#N)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XYKIUTSFQGXHOW-UHFFFAOYSA-N propan-2-one;toluene Chemical compound CC(C)=O.CC1=CC=CC=C1 XYKIUTSFQGXHOW-UHFFFAOYSA-N 0.000 description 1
- VOXVJVPRLDAJQV-UHFFFAOYSA-N propan-2-yl 2-[acetyl(benzyl)amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(C)OC(C1=C(N(CC2=CC=CC=C2)C(C)=O)SC2=C1C=CC(O)=C2Cl)=O VOXVJVPRLDAJQV-UHFFFAOYSA-N 0.000 description 1
- BESQLCCRQYTQQI-UHFFFAOYSA-N propan-2-yl 2-cyanoacetate Chemical compound CC(C)OC(=O)CC#N BESQLCCRQYTQQI-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 102200056447 rs17887074 Human genes 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 231100000064 subacute toxicity study Toxicity 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- IFPZSKSMXWKYGC-UHFFFAOYSA-N tert-butyl 2'-[acetyl(benzyl)amino]spiro[1,3-dioxolane-2,6'-5,7-dihydro-4H-1-benzothiophene]-3'-carboxylate Chemical compound CC(C)(C)OC(C1=C(N(CC2=CC=CC=C2)C(C)=O)SC(C2)=C1CCC21OCCO1)=O IFPZSKSMXWKYGC-UHFFFAOYSA-N 0.000 description 1
- WSAOXLYXIUHKCV-UHFFFAOYSA-N tert-butyl 2-[acetyl(benzyl)amino]-7-chloro-6-hydroxy-1-benzothiophene-3-carboxylate Chemical compound CC(C)(C)OC(C1=C(N(CC2=CC=CC=C2)C(C)=O)SC2=C1C=CC(O)=C2Cl)=O WSAOXLYXIUHKCV-UHFFFAOYSA-N 0.000 description 1
- BFNYNEMRWHFIMR-UHFFFAOYSA-N tert-butyl 2-cyanoacetate Chemical compound CC(C)(C)OC(=O)CC#N BFNYNEMRWHFIMR-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000007484 viral process Effects 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Definitions
- the invention relates to new biologically active compounds derivatives of 2-acetamido-6-hydroxy-benzothiophene of general formula (I), their pharmaceutically acceptable salts, showing activity against various viruses, mainly against the influenza virus and SARS-CoV-2 coronavirus, a method for their preparation and their use as antiviral drugs.
- the problem of finding new antiviral agents is due to the significant spread of viral infections in humans and animals. This is due to a decrease in immune protection in the human population, as well as the widespread development of resistance in viruses to the drugs available on the market.
- the problem of the rapid development of resistance is due to the fact that basically many of the known antiviral drugs used are derivatives of one class of compounds, as well as the lack of efficacy and often high toxicity of drugs.
- Influenza is an acute infectious disease of the respiratory tract caused by an RNA-containing virus, which has a high epidemiological and clinical significance with a high frequency of complications, especially among people at risk.
- Influenza and other acute respiratory viral infections (ARVI) viruses cause massive outbreaks of diseases that take on the character of epidemics every year. From 27 to 41 million cases of these diseases are registered annually, in particular, from 5 to 15% of the Russian population a year get sick with influenza.
- Influenza and ARVI remain practically uncontrolled diseases due to the high variability of the antigenic structure of circulating influenza viruses and the heterogeneity of ARVI pathogens.
- influenza viruses and other acute respiratory viral infections are able to change their properties and pathogenicity.
- influenza virus has a high mutation rate.
- the antigenic structure of the virus is highly susceptible to change as a result of the selective pressure of the host's immune system.
- chemotherapy drugs is perceived by the virus as a selection factor, as a result of which the formation of resistant strains also occurs.
- virus variants capable of both avoiding the activity of neutralizing antibodies, and thereby elude the body's immune response, and overcoming the action of chemotherapy drugs aimed at a certain stage of virus reproduction.
- each type of virus has its own mechanism of adaptation to a chemical preparation [Ison MG Antivirals and resistance: influenzavirus, Current OpinioninVirology, 2011, 563].
- Neuraminidase inhibitors are known, registered in Russia: Oseltamivir (Tamiflu) and Zanamivir (Relenza), as well as used in the USA: Peramivir (Rapiakta) and Laninamivir (Inavir), which act at the stage of budding of newly synthesized influenza virions from the cell membrane, blocking the cleavage of particles viral progeny from the cell surface [Ison M.G. Clinical use of approved influenza antivirals: therapy and prophylaxis. // Influenza Other RespirViruses. 2013, 7 Suppl 1, 7-13].
- inhibitors of viral neuraminidase interfere with the access of virions to target cells by blocking neuraminidase cleavage of mucopolysaccharides of the mucus of the upper respiratory tract.
- the practice of using neuraminidase inhibitors in the treatment of influenza has shown that the high efficiency of this group of drugs is limited by the early stage of the disease.
- Anti-influenza drugs of a different mechanism of action are also known, for example, the drug Remantadine (a-methyl-1-adamantylmethylamine hydrochloride) and Amantadine (1-aminoadamantane) [Davies, WL; Grunert, R.R.; Haff, RF; McGahen, JW; Neumayer, E.M.; Paulshock, M.; Watts, JC; Wood, TR; Hermann, EC; Hoffmann, CE Antiviral Activity of 1-Adamantanamine (Amantadine) // Science. - 1964. - V. 144. P. 862].
- Remantadine a-methyl-1-adamantylmethylamine hydrochloride
- Amantadine (1-aminoadamantane) Daavies, WL; Grunert, R.R.; Haff, RF; McGahen, JW; Neumayer, E.M.; Paulshock, M.
- the drug baloxaviramarboxil (Xofluza), an inhibitor of the endonuclease activity of the polymerase complex of the influenza virus, is registered in the United States (Yang T. Baloxavir Marboxil: The First Cap-dependent Endonuclease inhibitor for the treatmen to influenza. Ann Pharmacother. 2019, 53, 7, 754-759).
- Arbidol In Russia and a number of other countries, the drug Arbidol (umifenovir) is used to control influenza, blocking the fusogenic activity of viral hemagglutinin and thus preventing the fusion of viral and cell membranes [Blaising, J., Polyak, S.J., Pecheur, E-T, Arbidolas a broad- spectrumantiviral:anupdate. Antiviral Research (2014), doi: http://dx.doi.Org/10.1016/j.antiviral.2014.04.006]. In addition to direct antiviral activity, it has interferonogenic properties, so it can be used both for therapy and for the prevention of influenza infection.
- the disadvantage of drugs based on adamantane derivatives is the low antiviral activity caused by the resistance of the vast majority of influenza strains to this drug.
- Resistance is based on amino acid substitutions at or near the NA catalytic site.
- the H274Y mutation provides oseltamivir-resistance to viruses carrying the N1 subtype neuraminidase
- the El 19V and R292K mutations determine the resistance of the N2 subtype [McKimm-Breschkin JL Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Resp.
- Virus strains resistant to the new drug baloxavir have also been isolated from patients treated with this drug (Takashita E, Abe T, Morita H, Nagata S, et al. Influenza A (H1N1) pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment Antiviral Res. 2020, 180, 104828).
- influenza viruses demonstrate the ability to develop resistance to direct antiviral drugs, regardless of the mechanism of their activity.
- One way to overcome such resistance is the simultaneous use of several drugs that target different viral targets. In this case, the probability of selecting virus variants that are resistant to two or more drugs is greatly reduced.
- a number of studies have shown the formation of such double mutants resistant to both adamantane drugs and neuraminidase inhibitors [Sheu T.G., Fry A.M., Koch R.J. Dual Resistance to Adamantanes and Oseltamivir Among Seasonal Influenza A (H1N1) Viruses: 2008-2010. Journal of Infectious Diseases 2011, 203, 13].
- RNA viruses, influenza and coronavirus suggests the effectiveness of the use of systemic administration of interferon preparations (Viferon, Nitron, Reaferon, etc.) for basic nonspecific therapy of infections caused by them, taking into account the asthenia they cause.
- interferon preparations Viferon, Nitron, Reaferon, etc.
- the effectiveness of topical application of interferon solutions is doubtful and can be considered in the presence of local symptoms (rhinitis, pharyngitis, etc.).
- interferon inducers amiksin, cycloferon, neovir, etc. suggests the formation of secondary immunosuppression in 10-14 days, which can lead to re-infection in the ongoing epidemic period.
- Basic antiviral therapy drugs include targeted drugs that affect key viral processes: viral genome replication (remdesivir, triazavirin, favipiravir and the most powerful, but also the most toxic of the drugs in this group, ribavirin), viral neuraminidase activity (oseltamivir, zanamivir, peramivir) , proteolysis of viral polyproteins using virus-specific proteases (lopinavir, ritonavir, nelfinavir) [Yamamoto N., Matsuyama S., Hoshino T. Nefinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. BioRxiv 2020.04.06.026476 [Preprint]. 2020: biorxiv.org/content/10.1101/2020.04.06.026476vl]. Anti-replicative activity was traced for the purine derivative isoprinosine, which exhibits its activity against influenza viruses A and B types.
- pandemics of new respiratory infections will always begin in the absence of specific immune prophylaxis and therapy for these infections.
- the latter predetermines the need for early research and development of pathogenetic agents and methods for the prevention/treatment of respiratory viral infections based on the characteristics of the biology of coronaviruses and influenza A viruses.
- the objective of the present invention is to find new pharmacologically active compounds against viral infections, primarily against influenza and coronavirus, including strains resistant to currently existing drugs, which would have low toxicity and would not cause side effects in warm-blooded living organisms.
- the technical result is an increase in the effectiveness of antiviral agents, including against resistant strains of viruses, a decrease in the toxicity of antiviral agents, and an expansion of the arsenal of antiviral agents.
- R 1 is CN, COOH, COOAlk, CONHAlk, CON(Alk) 2 , CONH 2 ;
- R 2 is H, Hal, CH 2 (NAlk) 2 ;
- X is hydrogen or methyl
- Hal is fluorine, chlorine or bromine; each Aik group is a linear or branched alkyl group having from 1 to 4 carbon atoms, or in the N(Alk) 2 group, two Aik groups together with the nitrogen atom to which they are attached form a -(CH 2 )3-5-group, in which one of these -CH 2 - groups may be substituted by a nitrogen atom or a -N-CH3 group.
- R 1 is COOAlk or CONHAlk, in the group (CH2X)n X is H, n is 1.
- R 1 is COOMe
- R 1 is CONHMe
- R 1 is CN
- the invention also relates to pharmaceutically acceptable salts of the compounds of formula I.
- salts of a compound of formula (I) means salts of an inorganic or organic acid or base which have the desired pharmacological activity of the parent compound. These salts can be obtained in situ during the synthesis, isolation or purification of the compound of formula (I) or prepared specially.
- the pharmaceutically acceptable acid salts are characterized in that they contain the therapeutically active non-toxic acid addition salt forms which the compounds of formula I are capable of forming.
- Said acid addition salts can be prepared by treating the base compound represented by the general formula I with suitable acids, for example acids: hydrohalic acid, in particular hydrochloric acid, hydrobromic acid, sulfuric acid, nitric or phosphoric acid; organic acids, for example: acetic acid, hydroxyacetic acid, protionic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, maleic or fumaric acid, malic, tartaric or citric acid.
- suitable acids for example acids: hydrohalic acid, in particular hydrochloric acid, hydrobromic acid, sulfuric acid, nitric or phosphoric acid
- organic acids for example: acetic acid, hydroxyacetic acid, protionic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, maleic or fumaric acid, malic
- the compound in case the compound has a free COOH group, the compound can form alkali metal salts, for example the sodium salt.
- the compounds can be obtained and used in crystalline form.
- the compounds of general formula I and their pharmaceutically acceptable salts have antiviral activity and can be used in the treatment of diseases caused by a viral infection, in particular, caused by RNA-containing respiratory viruses or coronaviruses.
- the compounds of general formula I and their pharmaceutically acceptable salts can be used for the treatment or prophylaxis of influenza, for example influenza A, and/or diseases caused by SARS-CoV-2 coronavirus, for example SOUS-19.
- RNA-containing respiratory viruses or coronaviruses in particular, for example, caused by influenza virus or coronavirus SARS-CoV-2, such as influenza or SARS-19.
- the objective of the present invention is also solved, and the technical result is achieved by creating a pharmaceutical composition containing an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof as an active ingredient and at least one pharmaceutically acceptable excipient.
- “Pharmaceutical acceptable excipients” means diluents, excipients and/or pharmaceutical carriers used in the pharmaceutical field.
- Pharmaceutical carriers means carriers which are used in the pharmaceutical field in the preparation of a medicament.
- binders, lubricants, disintegrators, solvents, diluents, stabilizers, suspending agents, colorless agents, flavoring agents are used; in injection forms, antiseptic agents, solubilizers, stabilizers are used; topical forms use bases, diluents, lubricating agents, antiseptic agents.
- the pharmaceutical composition may be used as a medicament in tablet, capsule or topical form.
- the pharmaceutical composition can be obtained by mixing the active ingredient in an effective amount and the appropriate excipient.
- the objective of the present invention is also solved, and the technical result is achieved by using derivatives of 2-acetamido-6-hydroxy-benzothiophene of general formula I and their pharmaceutically acceptable salts, possibly in crystalline form, or a pharmaceutical composition based on them for the preparation of medicines for the prevention and treatment of diseases mediated viral infection caused by viruses such as RNA respiratory viruses or coronaviruses, in particular, for example, those caused by the influenza virus or KopoHaBHpycoMSARS-CoV-2. Diseases in particular can be influenza or SOS-19.
- the objective of the present invention is solved, and the technical result is also achieved by creating a method for preventing or treating a disease mediated by a viral infection, including the introduction or application to the subject of a 2-acetamido-6-hydroxy-benzothiophene derivative of the general structural formula I, its pharmaceutically acceptable salt or a pharmaceutical composition based on them in an effective amount.
- the viral infection may be an infection caused by RNA-containing respiratory viruses or coronaviruses, in particular, for example, caused by the influenza virus or the SARS-CoV-2 coronavirus.
- the method of treatment using a compound of the invention, a pharmaceutical composition or a drug based on them is also effective against strains resistant to currently existing drugs.
- High performance liquid chromatography with tandem mass spectroscopy was performed on an Agilent 1290 Infinity system, consisting of a triple quadrupole mass Agilent 6460 spectrometric detector, binary pump, mobile phase degasser, column oven and autosampler. Chromatographic separation was carried out on an Agilent Eclipse Plus C 18 RRHD column (2.1 x 50 mm, 1.8 ⁇ m) at 40°C. The volume of the injected sample is 2 ⁇ l.
- the mobile phase consisted of eluent A: 0.1% formic acid/water and eluent B: 0.1% formic acid and 85% acetonitrile in water.
- the elemental composition of the synthesized compounds was determined on a CHNS-analyzer Elemental Analyzer EURO EA. Melting points were determined on Electrothermal 9001 and have not been corrected.
- reaction progress and individuality of the substances were controlled by thin layer chromatography on Merck KGaA TLC Silicagel 60 F254 plates. Spots were detected by irradiation with UV light.
- Yields refer to purified products and are not optimized.
- Acetic anhydride 60 mmol was added to a suspension of compound 1 (30 mmol) in 80 ml of carbon tetrachloride and refluxed for 2 hours. The solution is evaporated under vacuum, water is added to the resulting residue and the precipitate is filtered off, washed with water, methanol or ethanol and diethyl ether.
- a side product of the reaction is ethyl 6-methoxy-2-(methylamino)-1-benzothiophene-3 carboxylate, which is formed in 3% yield. Yield 15: 77%. Mr. 95-97 °C. Mass (El), m/z ((%)): 251.3026[M] + (75). C12H13NO3S. d) Preparation of ethyl 2-amino-5-bromo-6-methoxy-1-benzothiophene-3-carboxylate 16.
- the synthesis method is similar to the synthesis of Za-s compounds.
- the reaction is carried out for 96 hours.
- Acetone is added to the residue obtained after evaporating the ethyl acetate, and the reaction product 18 is filtered off. Yield: 75%.
- Example 49 While cooling, boron tribromide (1.3 ml, 10 mmol) was added to a solution of compound 18 (0.64 g, 1 mmol) in 20 ml of chloroform, and the mixture was stirred at room temperature for 1 hour. Pour into 60 ml of ice water. The organic layer is separated, chloroform is evaporated, the residue is stirred with water for 30 min. The precipitate is filtered off, washed with water, ethyl alcohol, hexane. Crystallized from ethanol. Yield: 93%. Mr. 201-203 ° ⁇ . Mass (El), m/z ⁇ reiat- (%)): 448.3313[M] + (38). C 2 oHi 8 BrN0 4 S. 1 H NMR (300 MHz, DMSO-d 6 ) d 1.25
- Diethylamine solution is added to a solution of compound 5b (0.8 mmol) in 10 ml of methanol (0.31 g, 4.00 mmol), 0.5 ml of acetic acid and 37% aqueous formaldehyde solution (0.21 g, 3.00 mmol). The solution was stirred at room temperature for 48 hours. An aqueous solution of sodium carbonate (0.7 g in 5 ml of water) is added to the reaction mass and stirred for 30 minutes.
- Carbonyldiimidazole (2 mmol) was added to a solution of the corresponding starting compound 25a-g (1 mmol) in 10 ml of dry THF, and the mixture was stirred at room temperature for 1 hour. An anhydrous solution of methylamine in dioxane (3 mmol) is then added. And stir for 1 hour. The volatiles are removed under vacuum, the residue is added with water and extracted with ethyl acetate. The organic layer was washed with water 2 times. Ethyl acetate is evaporated, the residue is applied to the column (eluent hexane:acetone 10:4). Collect all fractions with the reaction product, evaporate the solvent. The residue is recrystallized from a mixture of toluene: ethyl acetate (10:1 or 10:4). A crystalline compound 26 is obtained.
- Example 78 Example 78.
- the synthesis is similar to the synthesis of the compounds according to examples 69-75, except for the amine used.
- Synthesis is similar to the synthesis of compounds according to examples 69-75.
- the microtetrazolium test was used to study the cytotoxicity of the compounds.
- MEM cell culture medium a series of threefold dilutions of each compound (300-0.1 ⁇ g/ml) was prepared on the MEM cell culture medium.
- MDCK cells were seeded in 96 well plates and incubated for 24 hours at 36° C. in 5% CO 2 until a monolayer formed.
- Serial dilutions of the test substances were added to the wells of the plates (0.2 ml per well) and incubated for 48 hours at 36°C in 5% CO2. The degree of destruction of the cell monolayer was then assessed in the microtetrazolium test (MTT).
- the cells were washed twice with physiological phosphate buffer and a solution of 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (ICN Biochemicalslnc., Aurora, Ohio) (0.5 mg/ml) in cell culture medium (0.1 ml per well). After 2 h of incubation, the wells were washed and the colored precipitate of formazan was dissolved in DMSO (0.1 ml per well) using a bacterial culture shaker. The optical density in the wells of the plate was then measured on an optical reader ThermoMultiskanFC (ThermoScientific, USA) at a wavelength of 540 nm.
- ThermoMultiskanFC ThermoScientific, USA
- Example 86 Determination of activity against influenza virus of 2-acetamido-6-hydroxy-benzothiophene derivatives of formula I.
- the antiviral activity of the compounds was assessed by the decrease in virus titer compared to the control.
- the virus titer was expressed as percent of control values (no drugs) and used for regression analysis as described above.
- a 50% effective dose (1C 50) was calculated for each compound, that is, the concentration at which the infectious titer of the virus decreased by half compared to the control (placebo), and the selectivity index (SI) (the ratio of CC50 to 1C 50 ).
- the calculated values of 1C 50 are given as the mean value ⁇ standard deviation for three experimental repetitions, and the results are presented in table. one.
- Example 87 Efficacy study of 2-acetamido-6-hydroxybenzothiophene derivatives in an in vivo viral infection model
- White outbred mice females weighing 16-18 g (age 5-6 weeks) were obtained from the nursery "Rappolovo" Leningrad region. Information about the experimental group was placed on the front surface of the cells and included the start date of the experiment, the date of infection, the name and mode of administration of the study drug. The animals were kept under standard conditions in accordance with the Decree of the Chief State Sanitary Doctor of the Russian Federation dated August 29, 2014 N°51 “On approval of SP 2.2.1.3218-14 “Sanitary and epidemiological requirements for the arrangement, equipment and maintenance of experimental biological clinics (vivariums)”.
- the cages are covered with steel lattice covers with aft recess.
- the floor area in the holding cage for one animal was 80 cm 2 (the minimum allowable area is 40 cm 2 ).
- Test samples 6 samples of 2-acetamide-6-hydroxy-benzothiophene derivatives (example 3, 23, 52, 61, 72, 73).
- Reference drugs Umifenovir, Oseltamivir and imidazolylethanamide pentanedioic acid. Before the experiment, the samples were dissolved or suspended in distilled water. The doses of the studied samples were calculated in relative weight units - mg/kg of animal body weight per day.
- mice 100 outbred adult female mice weighing 16-18 g (age 5-6 weeks) were used.
- the influenza virus A/PuertoRico/8/34 (H1N1) from the collection of viral strains of the NIIEM. Pasteur. Animals were infected intranasally under light ether anesthesia using an infecting dose of 2.5x10 3 EID50/animal at the rate of 0.025 ml of virus-containing material in each nostril.
- the study drugs were administered in daily doses 1 time per day in a volume of 0.2 ml.
- Compounds were administered orally using a disposable insulin syringe with a gastric tube.
- the studied samples were administered to animals according to the treatment and prophylactic scheme: 4 hours before infection, 4 hours after infection, then 1 time per day for 5 days. In total, 24 groups of animals were formed for the experiment.
- the death of animals in the experimental groups was recorded daily for 15 days after infection. As indicators of effectiveness in the experiment, an assessment of survival rates in groups (mortality rate (M), protection index (IZ)) was used.
- M memory rate
- IZ protection index
- the experiment was blinded, the samples were chilled, including the control.
- Example 88 Determination of the activity against the SARS-CoV-2 coronavirus of 2-acetamido-6-hydroxy-benzothiophene derivatives of formula I on U2-OS ACE2 cells.
- the plates are read using an automatic confocal microscope (Opera Phoenix) that measures the number of infected cells (GFP signal) and survival (Hoechst signal). Two experiments were carried out. The stock sample concentration for all samples was 25 tM. The results are presented in table. 3. IC50 indicates the concentration that inhibits infection by 50%.
- Example 89 Acute and subacute toxicity study of 2-acetamido-6-hydroxy-benzothiophene derivatives in mice. The study was carried out on adult mice of the BALB/c line, aged 8-12 weeks, weighing 20+2 g. Oral Toxicity - Fixed Dose Procedure” (see OECD online library data, URL: https://www.oecd-ilibrary.org/environment/test-no-420-acute-oral-toxicity-fixed- dose-procedure_9789264070943-en) when administered intragastrically to female mice. Acute toxicity was assessed in the preliminary (one animal at the maximum dose) and the main experiment. Further, subacute 14-day toxicity was assessed with a 14-day delayed observation period and an assessment of the local irritant effect when administered intragastrically to mice of both sexes at various doses.
- the studied substances were administered in fixed volumes in the range of tested doses.
- the volume administered to mice was 0.1 ml/10 g body weight.
- Substances were introduced as a suspension in 1% starch paste. Before dosing, animals were restricted in food for at least 3 hours before dosing, water was freely available.
- mice of both sexes were subjected to daily intragastric administration of the test substances indicated in Table 4 for a long time for 14 days at doses of 50, 100 and 200 mg/kg, as well as 1% starch paste in quality control.
- doses of 50, 100 and 200 mg/kg as well as 1% starch paste in quality control.
- the total number of animals was 192.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280026803.7A CN117222630A (zh) | 2021-02-12 | 2022-02-01 | 具有抗病毒活性的2-乙酰胺基-6-羟基-苯并噻吩衍生物 |
EP22753053.2A EP4293017A1 (en) | 2021-02-12 | 2022-02-01 | 2-acetamido-6-hydroxy-benzothiophene derivatives with antiviral activity |
CA3208028A CA3208028A1 (en) | 2021-02-12 | 2022-02-01 | 2-acetamido-6-hydroxy-benzothiophene derivatives with antiviral activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2021103521A RU2756587C9 (ru) | 2021-02-12 | 2021-02-12 | Производные 2-ацетамидо-6-гидрокси-бензотиофена и их фармацевтически приемлемые соли, обладающие противовирусной активностью |
RU2021103521 | 2021-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022173329A1 true WO2022173329A1 (ru) | 2022-08-18 |
Family
ID=78000224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2022/050030 WO2022173329A1 (ru) | 2021-02-12 | 2022-02-01 | Производные 2-ацетамидо-6-гидрокси-бензотиофена, обладающие противовирусной активностью |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4293017A1 (ru) |
CN (1) | CN117222630A (ru) |
CA (1) | CA3208028A1 (ru) |
RU (1) | RU2756587C9 (ru) |
WO (1) | WO2022173329A1 (ru) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005023818A2 (en) * | 2003-09-10 | 2005-03-17 | Gpc Biotech Ag | Heterobicyclic compounds as pharmaceutically active agents |
WO2009012430A1 (en) * | 2007-07-18 | 2009-01-22 | Janssen Pharmaceutica N.V. | Sulfonamides as trpm8 modulators |
RU2448692C2 (ru) | 2009-11-09 | 2012-04-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский Институт гриппа" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "НИИ гриппа" Минздравсоцразвития России) | Фармацевтические соли аминобицикло[2.2.1]гептанов как ингибиторы транскрипционного фактора nf-kb с противовирусной активностью (варианты) и их применение |
RU2530554C1 (ru) | 2013-04-22 | 2014-10-10 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова (НИОХ СО РАН) | Применение 1,7,7-триметилбицикло[2.2.1]гептан-2-илиден-аминоэтанола в качестве ингибитора репродукции вируса гриппа |
WO2017153789A1 (en) * | 2016-03-11 | 2017-09-14 | Vichem Chemie Kutató Kft. | Benzo[b]thiophene derivatives and their use for the inhibition of fibroblast growth factor receptor kinases (fgfrs) for the use of neo- and hyperplasia therapies |
EA202091889A1 (ru) * | 2018-02-08 | 2020-10-29 | Энио Фарма | Конденсированные производные тиофена и их применение |
-
2021
- 2021-02-12 RU RU2021103521A patent/RU2756587C9/ru active
-
2022
- 2022-02-01 WO PCT/RU2022/050030 patent/WO2022173329A1/ru active Application Filing
- 2022-02-01 CN CN202280026803.7A patent/CN117222630A/zh active Pending
- 2022-02-01 CA CA3208028A patent/CA3208028A1/en active Pending
- 2022-02-01 EP EP22753053.2A patent/EP4293017A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005023818A2 (en) * | 2003-09-10 | 2005-03-17 | Gpc Biotech Ag | Heterobicyclic compounds as pharmaceutically active agents |
WO2009012430A1 (en) * | 2007-07-18 | 2009-01-22 | Janssen Pharmaceutica N.V. | Sulfonamides as trpm8 modulators |
RU2448692C2 (ru) | 2009-11-09 | 2012-04-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский Институт гриппа" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "НИИ гриппа" Минздравсоцразвития России) | Фармацевтические соли аминобицикло[2.2.1]гептанов как ингибиторы транскрипционного фактора nf-kb с противовирусной активностью (варианты) и их применение |
RU2530554C1 (ru) | 2013-04-22 | 2014-10-10 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова (НИОХ СО РАН) | Применение 1,7,7-триметилбицикло[2.2.1]гептан-2-илиден-аминоэтанола в качестве ингибитора репродукции вируса гриппа |
WO2017153789A1 (en) * | 2016-03-11 | 2017-09-14 | Vichem Chemie Kutató Kft. | Benzo[b]thiophene derivatives and their use for the inhibition of fibroblast growth factor receptor kinases (fgfrs) for the use of neo- and hyperplasia therapies |
EA202091889A1 (ru) * | 2018-02-08 | 2020-10-29 | Энио Фарма | Конденсированные производные тиофена и их применение |
Non-Patent Citations (14)
Title |
---|
A.V. IVASHCHENKO ET AL.: "Sintez i protivovirusnaia aktivnost zameshchennykh etil-2-aminometil-5-gidroksi-1 N-indol-3-karbonovykh kislot i ikh proizvodnykh", KHIMIKO-FARMATSEVTICHESKII ZHURNAL, IZDATEL'STVO FOLIUM, RU, vol. 49, no. 3, 30 November 2014 (2014-11-30), RU , pages 7 - 19, XP009550708, ISSN: 0023-1134 * |
BLAISING, J.POLYAK, S.J.ECHEUR, E-I.: "Arbidolas a broad-spectrumantiviral: anupdate", ANTIVIRAL RESEARCH, 2014 |
BUCHRIESER, J ET AL., EMBOJ, 2020, pages e106267 |
CADY S.D.SCHMIDT-ROHR K.WANG J.SOTO C.S.DEGRADO W.F.HONG M.H.: "Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers", NATURE, vol. 463, 2010, pages 689 |
DAVIES, W.L.GRUNERT, R.R.HAFF, R.F.MCGAHEN, J.W.NEUMAYER, E.MPAULSHOCK, M.WATTS, J.CWOOD, T.R.HERMANN, E.CHOFFMANN, C.E: "Antiviral Activity of 1-Adamantanamine (Amantadine", SCIENCE, vol. 144, 1964, pages 862, XP002507819, DOI: 10.1126/science.144.3620.862 |
ISON M.G.: "Antivirals and resistance: influenzavirus", CURRENT OPINION IN VIROLOGY, 2011, pages 563 |
ISON M.G.: "Clinical use of approved influenza antivirals: therapy and prophylaxis", INFLUENZA OTHER RESPIR. VIRUSES., vol. 1, 2013, pages 7 - 13 |
MCKIMM-BRESCHKIN J. L.: "Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance", INFLUENZA OTHER RESP. VIRUSES, vol. 7, no. 1, 2013, pages 25 |
OKOMO-ADHIAMBO M.FRY A. M.SU S. ET AL.: "Oseltamivir-resistant influenza A (H1N1) pdm09 viruses", EMERG. INFECT. DIS, vol. 21, 2015, pages 136 |
PHARMACOTHER, vol. 53, no. 7, 2019, pages 754 - 759 |
SCHOLTISSEK C.QUACK G.KLENK H.D.WEBSTER R.G., ANTIVIRAL RES, vol. 37, 1998, pages 83 - 95 |
SHEU T.G.FRY A.M.GARTEN R.J: "Dual Resistance to Adamantanes and Oseltamivir Among Seasonal Influenza A (H1N1) Viruses", JOURNAL OF INFECTIOUS DISEASES, vol. 203, 2011, pages 13, XP055234265, DOI: 10.1093/infdis/jiq005 |
TAKASHITA EABE TMORITA HNAGATA S ET AL.: "Influenza A (H1N1) pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment", ANTIVIRAL RES, vol. 180, 2020, pages 104828, XP086226163, DOI: 10.1016/j.antiviral.2020.104828 |
YAMAMOTO N.MATSUYAMA S.HOSHINO T: "Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro", BIORXIV, 2020 |
Also Published As
Publication number | Publication date |
---|---|
CA3208028A1 (en) | 2022-08-18 |
EP4293017A1 (en) | 2023-12-20 |
RU2756587C9 (ru) | 2021-10-12 |
RU2756587C1 (ru) | 2021-10-01 |
CN117222630A (zh) | 2023-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102353413B1 (ko) | 인플루엔자 바이러스 복제 억제제 | |
Zhao et al. | Discovery of highly potent agents against influenza A virus | |
CN108290869B (zh) | 用于在流感病毒感染中使用的杂环吲哚 | |
CN108473493B (zh) | 用于流感病毒感染的官能化的戊酸 | |
JP6088639B2 (ja) | 抗マラリア薬 | |
KR20200069380A (ko) | 글루타르이미드 유도체, 이의 용도, 이를 기반으로 한 약학 조성물 및 글루타르이미드 유도체를 생산하는 방법 | |
JP2021514967A (ja) | ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法 | |
Krake et al. | Novel inhibitors of Plasmodium falciparum based on 2, 5-disubstituted furans | |
Camps et al. | Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs | |
CN112771048B (zh) | 流感病毒复制抑制剂及其中间体和用途 | |
Radix et al. | N, N′-disubstituted cinnamamide derivatives potentiate ciprofloxacin activity against overexpressing NorA efflux pump Staphylococcus aureus 1199B strains | |
RU2756587C9 (ru) | Производные 2-ацетамидо-6-гидрокси-бензотиофена и их фармацевтически приемлемые соли, обладающие противовирусной активностью | |
EA046411B1 (ru) | Производные 2-ацетамидо-6-гидроксибензотиофена, обладающие противовирусной активностью | |
CN112724156B (zh) | 一种多环吡啶酮衍生物和药物组合物及其应用 | |
RU2720305C1 (ru) | Замещенный 3,4,12,12а-тетрагидро-1Н-[1,4]оксазино[3,4-c]пиридо[2,1-f] [1,2,4]триазин-6,8-дион, фармацевтическая композиция, способы их получения и применения | |
US20150329515A1 (en) | Composition and method for treating or preventing influenza virus infection | |
WO2007120079A2 (fr) | Dérivés de 4-aminométhyl-6-brome-5-hydroxyindol-3-carboxylates | |
Barlow et al. | Synthesis and evaluation of 4-amino-3, 4-dihydro-2H-naphthalen-1-one derivatives as mast cell stabilising and anti-inflammatory compounds | |
Altenkämper et al. | Antimalarial and antitrypanosomal activity of a series of amide and sulfonamide derivatives of a 2, 5-diaminobenzophenone | |
CN114213395A (zh) | 一种嘧啶酮酰基哌嗪类化合物及其制备方法与应用 | |
JPS6214539B2 (ru) | ||
RU2649406C1 (ru) | 3-n-замещенные борнилпропионаты, используемые в качестве ингибиторов вируса марбург | |
RU2697716C1 (ru) | Гидрохлорид 1,7,7-триметилбицикло[2.2.1]гептан-2-ил 3-(пиперидин-1-ил)пропионат, используемый в качестве ингибитора вируса Эбола | |
Xie et al. | Discovery of a series of novel compounds with moderate anti-avian H5N1 influenza virus activity in chick embryo | |
Li et al. | Hybrid molecules based on an emodin scaffold. Synthesis and activity against SARS-CoV-2 and Plasmodium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22753053 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3208028 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18546127 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202392198 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022753053 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022753053 Country of ref document: EP Effective date: 20230912 |